DNAP.057.In for a gap,since news was out late today. (COMTEX)B: DNAPrint(TM) Launches ANCESTRYbyDNA(TM) 2.5, The Most Powerful
BGA Admixture Test Ever Developed ( PRNewswire )
B: DNAPrint(TM) Launches ANCESTRYbyDNA(TM) 2.5, The Most Powerful BGA Admixture
est Ever Developed ( PRNewswire )
SARASOTA, Fla., Jan 27, 2004 /PRNewswire via COMTEX/ -- DNAPrint(TM) genomics,
Inc. (OTC Bulletin Board: DNAP)(DNAPrint(TM) or the "Company") today introduced
a new version of its popular ANCESTRYbyDNA(TM) 2.0 test for the genetic
determination of BioGeographical Ancestry (BGA) admixture.
The new test, "ANCESTRYbyDNA(TM) 2.5" provides increased power and enhanced
sensitivity for genealogists because it is powered by 175 rather than 71
Ancestry Informative Markers (AIMs). The test is an augmented version of
ANCESTRYbyDNA(TM) 2.0; 104 new AIMs were added to the core set of 71 used in the
old test. Like the 2.0 version, ANCESTRYbyDNA(TM) 2.5 provides a customer's
proportional Native American, East Asian, Indo-European, and West Sub-Saharan
African BGA, but the increased number of markers allow for more sensitive and
accurate determinations of low levels of admixture (such as that which may have
been contributed by a single great grandparent). The enhanced sensitivity and
efficiency allowed DNAPrint(TM) to also upgrade the presentation of results for
the 2.5 version.
The human genome has millions of markers, or genetic variations, but only 1-2%
of these markers (0.002% of the genome) are ancestry informative. Because the
AIMs measured by the test are among the genomes best, and due to the enhanced
coverage of 8 AIMs per average chromosome, ANCESTRYbyDNA(TM) 2.5 represents the
most powerful test of its kind ever developed. The new test sells for $219 per
test. Customers who purchased the 2.0 version will receive an upgrade to 2.5 at
a reduced rate of $158.
The new test has been added to the www.ancestrybydna.com website. The Company is
typing samples from discrete populations, such as groups of individuals who
identify with a single ethnic or tribal group. The new website provides data
from simulations that address the accuracy and precision of the
ANCESTRYbyDNA(TM) tests. New data will be added to the website continuously as
it is produced, allowing customers an empirical frame of reference for
interpreting their results.
About DNAPrint(TM) genomics, Inc.
DNAPrint(TM) genomics, Inc., ("DNAPrint(TM)" or the "Company"), is a genomics
science company focused on the sale of proprietary genetic testing products and
services. The Company's core technologies for efficiently targeting single
nucleotide polymorphisms ("SNPs") enable it to provide predictive genetic tests
at a significant cost advantage over its competitors. The Company has identified
and patented the maps of certain SNPs with wide commercial applications called
Ancestry Informative Markers ("AIMS"). The Company believes that AIMs are the
key for unlocking the relationship between common variants and common
anthropometric, disease and drug response traits. Effectively mapping disease
and drug response sequences could lead to the development of clinical
classifiers for improving drug development, personalizing drug use and
empowering forensics investigations. The Company's patented AIMs are integral to
the Company's strategy of offering DNA tests that provide valuable predictive
results, including a person's physical characteristics, Biogeographical Ancestry
("BGA"), and predisposition to respond to certain pharmaceutical drugs. The
Company's tests target four distinct markets -- forensics, consumer,
pharmacogenomics (predicting drug response) and outsourced screening services.
The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol:
DNAP. For more information about the company, please visit www.dnaprint.com.
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities Exchange
Act as amended. Such statements are subject to risks and uncertainties that
could cause actual results to differ materially from those projected, including,
but not limited to, uncertainties relating to technologies, product development,
manufacturing, market acceptance, cost and pricing of DNAPrint's(TM) products,
dependence on collaborations and partners, regulatory approvals, competition,
intellectual property of others, and patent protection and litigation.
DNAPrint(TM) genomics, Inc. expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in DNAPrint's(TM) expectations with
regard thereto or any change in events, conditions, or circumstances on which
any such statements are based.
Media and Press Contacts
Richard Gabriel
DNAPrint(TM) genomics, Inc.
CEO/President
(941) 366-3400
SOURCE DNAPrint(TM) genomics, Inc.
CONTACT: Richard Gabriel, CEO and President, DNAPrint(TM) genomics,
Inc.,
+1-941-366-3400
URL: dnaprint.com
prnewswire.com |
